A Phase I Study of GZR18 Injection in Healthy Subjects

Exclusion Criteria

• •1\. History of dizziness with blood and needles.
• •2\. Known or suspected allergy to study related products; or a history of drug and food allergies; or a history of allergy-related diseases.
• •3\. Participants who participated in other clinical trials and were given the investigational drug or medical device intervention within 90 days prior to screening.
• •4\. Blood donation, surgery, or trauma with significant blood loss (more than or equal to 400 mL, except for menstrual blood loss in women) within 12 weeks prior to screening.
• •5\. Any clinically significant medical history judged by the investigator, including but not limited to: lung, gastrointestinal, liver, nervous system, kidney, genitourinary and endocrine, skin, or blood disorders, especially a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 , and a history of pancreatitis (acute or chronic).
• •6\. At screening or baseline, physical examination showed clinically significant abnormalities judged by the investigator.